Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axogen (AXGN) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Axogen (AXGN) over the last 16 years, with Q3 2025 value amounting to $2.8 million.

  • Axogen's Change in Accured Expenses rose 60547.45% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.3 million, marking a year-over-year increase of 21755.79%. This contributed to the annual value of $125000.0 for FY2024, which is 9807.96% down from last year.
  • As of Q3 2025, Axogen's Change in Accured Expenses stood at $2.8 million, which was up 60547.45% from $3.3 million recorded in Q2 2025.
  • In the past 5 years, Axogen's Change in Accured Expenses ranged from a high of $7.2 million in Q4 2024 and a low of -$9.1 million during Q1 2025
  • In the last 5 years, Axogen's Change in Accured Expenses had a median value of $685500.0 in 2021 and averaged $224388.9.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first soared by 431547.62% in 2023, then tumbled by 19856.67% in 2024.
  • Quarter analysis of 5 years shows Axogen's Change in Accured Expenses stood at $657000.0 in 2021, then surged by 132.88% to $1.5 million in 2022, then surged by 128.56% to $3.5 million in 2023, then surged by 107.32% to $7.2 million in 2024, then tumbled by 61.79% to $2.8 million in 2025.
  • Its last three reported values are $2.8 million in Q3 2025, $3.3 million for Q2 2025, and -$9.1 million during Q1 2025.